Hi,
I am part of a small sub group of EGFR members who are on 3 year adjuvant Osimertnib therapy.
Myself and fellow members of this community have been looking at available statistics around the ADAURA 3 year trial.
All of us are/were on adjuvant Osimertnib for 3 years, based on the above.
Some of us are now approaching the end of the 3 year limit that is currently imposed on this type of treatment.
Hence us looking at what statistics are available to guide us and our medical teams when deciding on our post 3 year monitoring/treatment pathways. E.g. frequency of scans, liquid biopsy's etc etc.
Does anyone know of anyone with expertise in this area, who could help us ? Particularly in the interpretation of the academic, medical statistics we seem to have discovered. I have e mailed a leading hospital and a lung cancer charity asking RMH and will chase replies.
The limited statistics (with small samples) seem to suggest to us that we should be requesting more frequent scans in the early years after stopping Osimertnib due to the higher rate of recurrence in those years.
We would be most grateful for any help you could provide.
Best Wishes
Hi Chas this is a very interesting question, but not one I can help with unfortunately. I wonder if you could ask on the Roy castle foundation?
I am sorry that my reply was not useful to you. We are all cancer patients in this group offering support to others with lung cancer, but have no expertise to statistics.
Maybe you can call the Macmillan support line on 0808 808 00 00 and speak to someone from Macmillan, or you could post your question in the Ask a Nurse section.
I would think that your oncologist has to follow guidelines for post treatment scans etc.
